CN Patent

CN113880814B — 一种嘧啶胺类化合物及应用

Assigned to Hangzhou Bio Sincerity Pharma Tech Co ltd · Expires 2024-01-05 · 2y expired

What this patent protects

本发明公开了一种具有通式Ⅰ结构的嘧啶胺类化合物及应用，该类化合物属于激酶CDK4、CDK6和/或CDK9抑制剂，可更广泛地用于多种癌症的治疗，具有巨大的临床应用价值。

USPTO Abstract

本发明公开了一种具有通式Ⅰ结构的嘧啶胺类化合物及应用，该类化合物属于激酶CDK4、CDK6和/或CDK9抑制剂，可更广泛地用于多种癌症的治疗，具有巨大的临床应用价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN113880814B
Jurisdiction
CN
Classification
—
Expires
2024-01-05
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Bio Sincerity Pharma Tech Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.